MX2013005915A - Inhibidores de kat ii. - Google Patents
Inhibidores de kat ii.Info
- Publication number
- MX2013005915A MX2013005915A MX2013005915A MX2013005915A MX2013005915A MX 2013005915 A MX2013005915 A MX 2013005915A MX 2013005915 A MX2013005915 A MX 2013005915A MX 2013005915 A MX2013005915 A MX 2013005915A MX 2013005915 A MX2013005915 A MX 2013005915A
- Authority
- MX
- Mexico
- Prior art keywords
- hydroxy
- amino
- kat
- inhibitors
- dihydroquinolin
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- ZCXUBYJYCFIKOU-UHFFFAOYSA-N 3-amino-1-hydroxy-2-oxo-3,4-dihydroquinoline-7-carbonitrile Chemical compound C1=C(C#N)C=C2N(O)C(=O)C(N)CC2=C1 ZCXUBYJYCFIKOU-UHFFFAOYSA-N 0.000 abstract 1
- WNRHEZRHORCVMD-UHFFFAOYSA-N 3-amino-1-hydroxy-7-(2-methoxyethoxy)-3,4-dihydroquinolin-2-one Chemical compound C1C(N)C(=O)N(O)C2=CC(OCCOC)=CC=C21 WNRHEZRHORCVMD-UHFFFAOYSA-N 0.000 abstract 1
- QGEZZOCZCRMNJM-YMNIQAILSA-N 3-amino-1-hydroxy-7-[(2s)-1-methoxypropan-2-yl]oxy-3,4-dihydroquinolin-2-one Chemical compound C1C(N)C(=O)N(O)C2=CC(O[C@@H](C)COC)=CC=C21 QGEZZOCZCRMNJM-YMNIQAILSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41879110P | 2010-12-01 | 2010-12-01 | |
| US41923210P | 2010-12-02 | 2010-12-02 | |
| PCT/IB2011/055190 WO2012073146A1 (en) | 2010-12-01 | 2011-11-18 | Kat ii inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013005915A true MX2013005915A (es) | 2013-07-03 |
Family
ID=45315857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013005915A MX2013005915A (es) | 2010-12-01 | 2011-11-18 | Inhibidores de kat ii. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8487104B2 (enExample) |
| EP (1) | EP2646417A1 (enExample) |
| JP (1) | JP5868994B2 (enExample) |
| KR (1) | KR101522803B1 (enExample) |
| CN (1) | CN103228631B (enExample) |
| AR (1) | AR084051A1 (enExample) |
| AU (1) | AU2011336217B2 (enExample) |
| CA (1) | CA2819106C (enExample) |
| IL (1) | IL226668A (enExample) |
| MX (1) | MX2013005915A (enExample) |
| SG (1) | SG190246A1 (enExample) |
| WO (1) | WO2012073146A1 (enExample) |
| ZA (1) | ZA201303412B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2861593A1 (en) * | 2012-06-15 | 2015-04-22 | Pfizer Inc. | Tricyclic compounds as kat ii inhibitors |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| TWI693227B (zh) * | 2014-04-23 | 2020-05-11 | 日商田邊三菱製藥股份有限公司 | 新穎二環性或三環性雜環化合物 |
| EA034167B8 (ru) | 2015-05-22 | 2021-04-27 | Эйджинбайо, Инк. | Фармацевтические композиции леветирацетама пролонгированного высвобождения |
| EP3372601B1 (en) | 2015-10-22 | 2022-09-21 | Mitsubishi Tanabe Pharma Corporation | Novel bicyclic heterocyclic compound |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4208304A1 (de) * | 1992-03-16 | 1993-09-23 | Merck Patent Gmbh | 2-oxochinolinderivate |
| US5594006A (en) * | 1993-03-18 | 1997-01-14 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives as matrix metalloproteinases inhibitors |
| JPH0881443A (ja) * | 1994-09-12 | 1996-03-26 | Otsuka Pharmaceut Co Ltd | 細胞外マトリックス金属プロテアーゼ阻害剤 |
| WO2005007628A1 (en) * | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US20100273787A1 (en) * | 2007-11-15 | 2010-10-28 | Robert Schwarcz | Kynurenine-aminotransferase inhibitors |
| JP5643818B2 (ja) * | 2009-06-18 | 2014-12-17 | ファイザー・インク | Ｋａｔｉｉ阻害剤としての二環式および三環式化合物 |
| DK2646443T3 (en) | 2010-12-01 | 2014-11-17 | Pfizer | CAT-II inhibitors |
-
2011
- 2011-11-18 WO PCT/IB2011/055190 patent/WO2012073146A1/en not_active Ceased
- 2011-11-18 EP EP11794240.9A patent/EP2646417A1/en not_active Withdrawn
- 2011-11-18 AU AU2011336217A patent/AU2011336217B2/en not_active Ceased
- 2011-11-18 MX MX2013005915A patent/MX2013005915A/es not_active Application Discontinuation
- 2011-11-18 KR KR1020137016959A patent/KR101522803B1/ko not_active Expired - Fee Related
- 2011-11-18 JP JP2013541447A patent/JP5868994B2/ja not_active Expired - Fee Related
- 2011-11-18 CA CA2819106A patent/CA2819106C/en not_active Expired - Fee Related
- 2011-11-18 CN CN201180057792.0A patent/CN103228631B/zh not_active Expired - Fee Related
- 2011-11-18 SG SG2013036314A patent/SG190246A1/en unknown
- 2011-11-30 AR ARP110104458A patent/AR084051A1/es not_active Application Discontinuation
- 2011-11-30 US US13/307,140 patent/US8487104B2/en not_active Expired - Fee Related
-
2013
- 2013-05-10 ZA ZA2013/03412A patent/ZA201303412B/en unknown
- 2013-05-30 IL IL226668A patent/IL226668A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN103228631A (zh) | 2013-07-31 |
| JP5868994B2 (ja) | 2016-02-24 |
| CA2819106C (en) | 2015-12-29 |
| US20120142729A1 (en) | 2012-06-07 |
| CA2819106A1 (en) | 2012-06-07 |
| JP2014500885A (ja) | 2014-01-16 |
| HK1187611A1 (en) | 2014-04-11 |
| WO2012073146A1 (en) | 2012-06-07 |
| CN103228631B (zh) | 2015-04-29 |
| ZA201303412B (en) | 2014-07-30 |
| KR101522803B1 (ko) | 2015-05-26 |
| KR20130098421A (ko) | 2013-09-04 |
| US8487104B2 (en) | 2013-07-16 |
| AU2011336217A1 (en) | 2013-06-06 |
| IL226668A (en) | 2016-07-31 |
| EP2646417A1 (en) | 2013-10-09 |
| SG190246A1 (en) | 2013-06-28 |
| AU2011336217B2 (en) | 2015-10-01 |
| AR084051A1 (es) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011013870A (es) | Compuestos biciclicos y triciclicos como inhibidores de quinurenina aminotransferasa ii. | |
| NZ624063A (en) | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors | |
| MY180751A (en) | 3,4-dihydroisoquinolin-2(1h)-yl compounds | |
| PH12015502502A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| PH12013501556A1 (en) | IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
| NZ624068A (en) | Fused tricyclic compounds as raf kinase inhibitors | |
| MY165728A (en) | Selective glycosidase inhibitors and uses thereof | |
| EA201591689A1 (ru) | НОВЫЕ N-АЦИЛ-(3-ЗАМЕЩЕННЫЕ)-(8-ЗАМЕЩЕННЫЕ)-5,6-ДИГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И МЕТОДЫ ИСПОЛЬЗОВАНИЯ ПРИ РАССТРОЙСТВАХ,ОПОСРЕДОВАННЫХ РЕЦЕПТОРОМ NK-3 | |
| CL2012001139A1 (es) | Compuestos derivados de imidazo[1.2-b]piridazina, inhibidores de pde10; composicion farmaceutica; procedimiento de preparacion; util para el tratamiento o prevencion de un trastorno del snc, tales como trastornos psicoticos, de ansiedad, del movimiento, del humor, neurodegenerativos, metabolicos y del dolor, entre otros. | |
| CL2015000096A1 (es) | Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros | |
| MX364602B (es) | Inhibidores selectivos de glicosidasa y usos de los mismos. | |
| PH12015501707B1 (en) | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use | |
| MD20150023A2 (ro) | Piridinone biciclice noi | |
| NZ630489A (en) | Bicyclic pyrazinone derivatives | |
| EP2596133A4 (en) | METHOD FOR DETECTING NEUROLOGICAL OR NEUROPSYCHIATRICAL ILLNESSES OR SUFFERING | |
| CL2011002382A1 (es) | Uso de un compuesto derivado de quinazolina-2,4-diona para el tratamiento y/o la prevencion de trastornos asociados al sistema nervioso central y/o al sistema nervioso periferico, preferentemente trastornos asociados a esquizofrenia, enfermedad de parkinson y enfermedad de alzheimer. | |
| MX362939B (es) | Derivados de (aza-)isoquinolinona. | |
| PH12016501863A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| GEP201606552B (en) | Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| PH12016501993A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| IN2014DN09826A (enExample) | ||
| EA201171393A1 (ru) | 7-([1,2,4]ТРИАЗОЛО[1,5α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН И ЕГО ПРИМЕНЕНИЕ | |
| EP2242364A4 (en) | PREPARATION AND SANANTIOMERIC SEPARATION OF NONANE OF 7- (3-PYRIDINYL) -1,7-DIAZASPIROÝ4.4 AND NEW FORMS OF SALT OF RACEMATE AND ENANTIOMERS | |
| WO2012168213A3 (en) | Novel process for the synthesis of 7-chloro-4-(piperazin-1-yl)-quinoline | |
| MX2009011541A (es) | Derivados de isoquinolinona como antagonistas nk3. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |